Copeptin in the Diagnosis of Diabetes Insipidus

TO THE EDITOR: In their study of the value of copeptin for diagnosing diabetes insipidus, Fenske et al. (Aug. 2 issue)¹ overlook two possible methodologic flaws. First, some of their patients appear to have had an element of a solute diuresis. For example, among patients with primary polydipsia, the product of the baseline median urine osmolality (408 mOsm per kilogram) and a urine volume of 4 liters per day or more indicates that in some patients the daily urine solute load was more than 1600 mOsm, which greatly exceeds the normal value (approximately 10 mOsm per kilogram per day).^{2,3} Second, the water-deprivation test was incomplete. The goal is to raise the serum sodium and endogenous vasopressin levels sufficiently to induce maximal urine concentration, as shown by stability of the urine osmolality.^{4,5} This critical step was omitted. Therefore, we cannot know whether the stimulus was adequate and whether restricting water longer would have changed the results. That the serum sodium levels were notably higher after the administration of hypertonic saline than after water deprivation suggests that it might have. Thus, the authors' conclusion that measurement of hypertonic saline-stimulated copeptin is superior to water-deprivation testing seems premature.

Aaron Spital, M.D.

Mount Sinai St. Luke's
New York, NY
aspital@att.net

No potential conflict of interest relevant to this letter was reported.

1. Fenske W, Refardt J, Chifu I, et al. A copeptin-based approach in the diagnosis of diabetes insipidus. *N Engl J Med* 2018;379:428-39.
2. Bhasin B, Velez JC. Evaluation of polyuria: the roles of solute loading and water diuresis. *Am J Kidney Dis* 2016;67:507-11.
3. Robertson GL. Differential diagnosis of polyuria. *Annu Rev Med* 1988;39:425-42.
4. Miller M, Dalakos T, Moses AM, Fellerman H, Streeten DH. Recognition of partial defects in antidiuretic hormone secretion. *Ann Intern Med* 1970;73:721-9.
5. Zerbe RL, Robertson GL. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. *N Engl J Med* 1981;305:1539-46.

DOI: 10.1056/NEJMc1811694

TO THE EDITOR: I was disappointed in the article by Fenske et al., which seemed to claim that the assay of plasma copeptin is the best way to dif-

ferentiate partial central (pituitary) diabetes insipidus from primary polydipsia. Limitations on length for letters to the editor preclude a complete listing of the many apparent oddities and deficiencies in the data and conclusions. Suffice it to note that the copeptin values during infusion of 3% saline are not expressed relative to the concurrent plasma sodium level. Therefore, the interpretation fails to take into account the large differences in the level of osmotic stimulation between the two groups. In addition, the accuracy of the interpretation is based on the opinion of experts and not on the effect of a closely monitored trial of desmopressin therapy (the most reliable standard). Most troubling of all, the diagnosis made from the copeptin data correlates poorly with the presence or absence of the posterior pituitary "bright spot" on magnetic resonance imaging. When plasma arginine vasopressin is used for differential diagnosis, the bright spot is always present in primary polydipsia but absent or small in partial pituitary diabetes insipidus.¹

Gary L. Robertson, M.D.

Northwestern University School of Medicine
Chicago, IL
robconsult@mhtc.net

No potential conflict of interest relevant to this letter was reported.

1. Robertson GL. Diabetes insipidus: differential diagnosis and management. *Best Pract Res Clin Endocrinol Metab* 2016;30:205-18.

DOI: 10.1056/NEJMc1811694

TO THE EDITOR: The diagnostic and prognostic yields of copeptin, a surrogate biomarker of arginine vasopressin secretion, are currently investigated in various disorders linked to arginine vasopressin regulation, including heart failure, sepsis, or the metabolic syndrome.¹ More specifically, patients with autosomal dominant polycystic kidney disease (ADPKD), which has a prevalence of 1 in 400 to 1000 live births, show significantly higher plasma copeptin levels than controls.² Plasma copeptin levels independently correlate with ADPKD progression.³ Copeptin secretion after hypertonic saline stimulation in patients with ADPKD is unknown.

In the study involving 144 patients with hypotonic polyuria, Fenske et al. elegantly show that

measuring plasma copeptin after infusion of 3% saline over a period of 3 hours has greater diagnostic accuracy than 17-hour water deprivation. This test will probably replace the water-deprivation test in the diagnostic workup of polyuria, with a copeptin cutoff level of more than 4.9 pmol per liter.⁴ It is not clearly mentioned that this cutoff value is a delta — that is, a change in the plasma copeptin level at a plasma sodium level of 147 mmol per liter or more versus baseline. It would have been relevant to provide pretest copeptin levels according to subgroup. Indeed, specific conditions, such as ADPKD, are essentially characterized by an increased plasma copeptin level, a fact that may pragmatically skew the diagnostic yield of copeptin measurement after hypertonic saline stimulation in the challenging context of hypotonic polyuria.

Djalila Mekahli, M.D., Ph.D.

University Hospitals Leuven
Leuven, Belgium

François Jouret, M.D., Ph.D.

University of Liège Hospital
Liège, Belgium
francois.jouret@chuliege.be

No potential conflict of interest relevant to this letter was reported.

1. Dobbs L, Edozien KC. Copeptin and its potential role in diagnosis and prognosis of various diseases. *Biochem Med (Zagreb)* 2013;23:172-90.
2. Zitteba D, van den Berg E, Meijer E, et al. Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. *Clin J Am Soc Nephrol* 2014;9:1553-62.
3. Boertien WE, Meijer E, Li J, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. *Am J Kidney Dis* 2013;61:420-9.
4. Rosen CJ, Ingelfinger JR. A reliable diagnostic test for hypotonic polyuria. *N Engl J Med* 2018;379:483-4.

DOI: 10.1056/NEJMc1811694

THE AUTHORS REPLY: Spital correctly notes that solute excretion determines free-water excretion. However, solute diuresis as a main cause of chronic polyuria is unlikely, because enrollment required hypotonic polyuria during screening diagnostics and exclusion of patients with glucosuria and electrolyte diuresis. The given baseline urine osmolality was assessed with the use of spot urine samples obtained the morning of the testing day, at which point most patients had been fluid-restricted overnight.

It is possible that a more extended dehydration period might have affected the diagnosis derived from the indirect test in individual patients. However, the 17-hour fluid deprivation is well in line with the previously reported dehydration periods required to induce maximal urine concentration (8 to 18 hours)¹ and confirms diagnostic inferiority of the indirect water-deprivation test as compared with the direct test of arginine vasopressin function.² Importantly, because this 17-hour water-deprivation protocol was already cumbersome for patients, the test involving the infusion of 3% saline is arguably more reliable and convenient.

A therapeutic trial with desmopressin alone, as suggested by Robertson, is neither a good nor an accepted standard to differentiate diabetes insipidus from primary polydipsia. Taking the treatment response into account — as we did in our diagnostic reference standard — enables high diagnostic accuracy.

Robertson's second point, regarding the presence of a bright spot in all patients with primary polydipsia, also lacks evidence. Although the diagnostic accuracy of the bright spot has never been prospectively investigated, an age-related absence of a pituitary bright spot was previously reported in up to 20% of normal healthy humans,³ and other studies have shown the presence of a bright spot in patients with clinical evidence of central diabetes insipidus.⁴ Our data provide evidence that neither its specificity nor its sensitivity is high enough to use the presence or absence of a pituitary bright spot as a diagnostic measure.

Preserving tradition,² we show the plasma copeptin levels during the infusion of 3% saline relative to serum sodium levels in Figure S2 in the Supplementary Appendix (available with the full text of our article at NEJM.org). More importantly, given the feasibility of the test interpretation in the clinical routine, the test involving the infusion of 3% saline was deliberately designed to nearly equalize the level of osmotic stimulation in all patient groups (Fig. S4 in the Supplementary Appendix).

We thank Mekahli and Jouret for mentioning the value of copeptin as a prognostic surrogate in patients with ADPKD. With respect to the diagnostic application of copeptin in hypotonic polyuria, it is important to clarify that pretests according to subgroup had been provided⁵ and were

prospectively validated; this confirmed a stimulated copeptin level of 4.9 pmol per liter as an absolute cutoff value, not a delta.

Patients with ADPKD generally have a form of nephrogenic diabetes insipidus, which may be clinically masked in patients receiving dialysis. For the probably very rare condition of suspected central diabetes insipidus in a patient with ADPKD, no data are yet available.

Wiebke Fenske, M.D., Ph.D.

University of Leipzig
Leipzig, Germany

Julie Refardt, M.D.

Mirjam Christ-Crain, M.D., Ph.D.

University of Basel
Basel, Switzerland
mirjam.christ-crain@unibas.ch

Since publication of their article, the authors report no further potential conflict of interest.

1. Miller M, Dalakos T, Moses AM, Fellerman H, Streeten DH. Recognition of partial defects in antidiuretic hormone secretion. *Ann Intern Med* 1970;73:721-9.
2. Zerbe RL, Robertson GL. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. *N Engl J Med* 1981;305:1539-46.
3. Brooks BS, el Gammal T, Allison JD, Hoffman WH. Frequency and variation of the posterior pituitary bright signal on MR images. *AJNR Am J Neuroradiol* 1989;10:943-8.
4. Maghnie M, Genovese E, Bernasconi S, Binda S, Aricò M. Persistent high MR signal of the posterior pituitary gland in central diabetes insipidus. *AJNR Am J Neuroradiol* 1997;18:1749-52.
5. Timper K, Fenske W, Kühn F, et al. Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria-polydipsia syndrome: a prospective multicenter study. *J Clin Endocrinol Metab* 2015;100:2268-74.

DOI: 10.1056/NEJMc1811694

Correspondence Copyright © 2018 Massachusetts Medical Society.

INSTRUCTIONS FOR LETTERS TO THE EDITOR

Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere.

Letters accepted for publication will appear in print, on our website at NEJM.org, or both.

Please note the following:

- Letters in reference to a *Journal* article must not exceed 175 words (excluding references) and must be received within 3 weeks after publication of the article.
- Letters not related to a *Journal* article must not exceed 400 words.
- A letter can have no more than five references and one figure or table.
- A letter can be signed by no more than three authors.
- Financial associations or other possible conflicts of interest must be disclosed. Disclosures will be published with the letters. (For authors of *Journal* articles who are responding to letters, we will only publish new relevant relationships that have developed since publication of the article.)

- Include your full mailing address, telephone number, fax number, and email address with your letter.
- All letters must be submitted through our online submission system at NEJM.org.

Letters that do not adhere to these instructions will not be considered. We will notify you when we have made a decision about possible publication. Letters regarding a recent *Journal* article may be shared with the authors of that article. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the *Journal's* various print and electronic publications and in collections, revisions, and any other form or medium.

NOTICES

Notices submitted for publication should contain a mailing address and telephone number of a contact person or department. We regret that we are unable to publish all notices received.

2ND SOUTHERN AFRICAN CONGRESS OF INTEGRATIVE MEDICINE

The congress will be held in Cape Town, South Africa, Nov. 17 and 18.

Contact the Registration and Accommodation Manager, Paradigm Conferences and Events, Unit 13A, Edgemoor Business Park, Southdale Road, Edgemoor Western Cape, South Africa; or call +27(0)820530431; or e-mail registration@paradigmconventions.com; or see <http://www.integrativemedcongress.com/>.

NEPHROLOGY 2019

The course will be offered in Boston, March 17–22. It is jointly presented by Harvard Medical School and Beth Israel Deaconess Medical Center. Deadline for early registration is Jan. 4.

Contact Agri Meetings, P.O. Box 825, Boston, MA 02117-0825; or call (617) 384-8600; or fax (978) 304-0936; or e-mail ceprograms@hms.harvard.edu; or see <http://www.nephrologyboston.com>.

ADVANCED EUROPEAN BIOETHICS COURSE

The course, entitled “Suffering, Death and Palliative Care,” will be offered in Nijmegen, the Netherlands, March 19–22. It is presented by the section of Healthcare Ethics, Department IQ healthcare, Radboud University Nijmegen Medical Centre.

Contact Valesca Hulsman, IQ healthcare, P.O. Box 9101, 114, 6500 HB Nijmegen, the Netherlands; or call +31 (0)24 3615305; or e-mail Valesca.Hulsman@radboudumc.nl; or see <http://www.iqhealthcare.nl/en/education/international-courses>.

UPDATE IN INTERNAL MEDICINE 2018

The course will be offered in Boston, Dec. 2–8. It is jointly sponsored by Harvard Medical School and Beth Israel Deaconess Medical Center.

Contact Agri Meetings, P.O. Box 825, Boston, MA 02117-0825; or call (617) 384-8600; or fax (978) 304-0936; or e-mail ceprograms@hms.harvard.edu; or see <http://www.updateinternalmedicine.com>.

THE JOURNAL'S WEB AND EMAIL ADDRESSES

To submit a letter to the Editor: authors.NEJM.org
For information about the status of a submitted manuscript: authors.NEJM.org
To submit a meeting notice: meetingnotices@NEJM.org
The *Journal's* web pages: NEJM.org